Cargando…
Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
INTRODUCTION: Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insufficient real-world data supporting shortening of...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710286/ https://www.ncbi.nlm.nih.gov/pubmed/36457986 http://dx.doi.org/10.5114/aoms.2019.86569 |
_version_ | 1784841332927234048 |
---|---|
author | Zarębska-Michaluk, Dorota Piekarska, Anna Jaroszewicz, Jerzy Klapaczyński, Jakub Sitko, Marek Tudrujek-Zdunek, Magdalena Tomasiewicz, Krzysztof Belica-Wdowik, Teresa Pabjan, Paweł Lorenc, Beata Czauż-Andrzejuk, Agnieszka Tronina, Olga Krygier, Rafał Dobracki, Witold Buczyńska, Iwona Simon, Krzysztof A. Dybowska, Dorota Halota, Waldemar Pawłowska, Małgorzata Citko, Jolanta Laurans, Łukasz Mazur, Włodzimierz Janczewska, Ewa Socha, Łukasz Deroń, Zbigniew Berak, Hanna Flisiak, Robert |
author_facet | Zarębska-Michaluk, Dorota Piekarska, Anna Jaroszewicz, Jerzy Klapaczyński, Jakub Sitko, Marek Tudrujek-Zdunek, Magdalena Tomasiewicz, Krzysztof Belica-Wdowik, Teresa Pabjan, Paweł Lorenc, Beata Czauż-Andrzejuk, Agnieszka Tronina, Olga Krygier, Rafał Dobracki, Witold Buczyńska, Iwona Simon, Krzysztof A. Dybowska, Dorota Halota, Waldemar Pawłowska, Małgorzata Citko, Jolanta Laurans, Łukasz Mazur, Włodzimierz Janczewska, Ewa Socha, Łukasz Deroń, Zbigniew Berak, Hanna Flisiak, Robert |
author_sort | Zarębska-Michaluk, Dorota |
collection | PubMed |
description | INTRODUCTION: Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insufficient real-world data supporting shortening of treatment. The aim of our study was to compare 8- and 12-week regimens’ efficacy in patients eligible for 8-week therapy in a real-world setting. MATERIAL AND METHODS: Data of HCV genotype 1 infected patients treated with LDV/SOF between 2015 and 2018 included in the EpiTer-2 database were analyzed with respect to patients’ characteristics and length of treatment. RESULTS: Among a total of 1718 patients treated with LDV/SOF, 679 were included in the analysis, 238 (35%) received 8-week regimen, whereas 441 were treated for 12 weeks although they fulfilled the criteria for a shorter course. The majority of patients were infected with genotype 1b (89%) and demonstrated minimal fibrosis (55%). The 12-week regimen was assigned significantly more frequently to patients with comorbidities, concomitant medications and advanced liver fibrosis. The sustained virologic response rate was similar after 8 (98%) and 12 (97%) weeks of therapy according to intent-to-treat analysis and reached 99% in both groups after exclusion of patients lost to follow-up. CONCLUSIONS: We confirmed high effectiveness regardless of treatment duration with LDV/SOF in non-cirrhotics infected with HCV genotype 1 eligible for the 8-week regimen according to the current label. This real-world study also demonstrated no need for addition of ribavirin (RBV) in this population and showed that shortening of treatment significantly improves the safety profile of LDV/SOF medication. |
format | Online Article Text |
id | pubmed-9710286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-97102862022-11-30 Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting Zarębska-Michaluk, Dorota Piekarska, Anna Jaroszewicz, Jerzy Klapaczyński, Jakub Sitko, Marek Tudrujek-Zdunek, Magdalena Tomasiewicz, Krzysztof Belica-Wdowik, Teresa Pabjan, Paweł Lorenc, Beata Czauż-Andrzejuk, Agnieszka Tronina, Olga Krygier, Rafał Dobracki, Witold Buczyńska, Iwona Simon, Krzysztof A. Dybowska, Dorota Halota, Waldemar Pawłowska, Małgorzata Citko, Jolanta Laurans, Łukasz Mazur, Włodzimierz Janczewska, Ewa Socha, Łukasz Deroń, Zbigniew Berak, Hanna Flisiak, Robert Arch Med Sci Clinical Research INTRODUCTION: Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but in practice this regimen is frequently extended up to 12 weeks at least in part due to insufficient real-world data supporting shortening of treatment. The aim of our study was to compare 8- and 12-week regimens’ efficacy in patients eligible for 8-week therapy in a real-world setting. MATERIAL AND METHODS: Data of HCV genotype 1 infected patients treated with LDV/SOF between 2015 and 2018 included in the EpiTer-2 database were analyzed with respect to patients’ characteristics and length of treatment. RESULTS: Among a total of 1718 patients treated with LDV/SOF, 679 were included in the analysis, 238 (35%) received 8-week regimen, whereas 441 were treated for 12 weeks although they fulfilled the criteria for a shorter course. The majority of patients were infected with genotype 1b (89%) and demonstrated minimal fibrosis (55%). The 12-week regimen was assigned significantly more frequently to patients with comorbidities, concomitant medications and advanced liver fibrosis. The sustained virologic response rate was similar after 8 (98%) and 12 (97%) weeks of therapy according to intent-to-treat analysis and reached 99% in both groups after exclusion of patients lost to follow-up. CONCLUSIONS: We confirmed high effectiveness regardless of treatment duration with LDV/SOF in non-cirrhotics infected with HCV genotype 1 eligible for the 8-week regimen according to the current label. This real-world study also demonstrated no need for addition of ribavirin (RBV) in this population and showed that shortening of treatment significantly improves the safety profile of LDV/SOF medication. Termedia Publishing House 2019-07-11 /pmc/articles/PMC9710286/ /pubmed/36457986 http://dx.doi.org/10.5114/aoms.2019.86569 Text en Copyright: © 2019 Termedia & Banach https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Clinical Research Zarębska-Michaluk, Dorota Piekarska, Anna Jaroszewicz, Jerzy Klapaczyński, Jakub Sitko, Marek Tudrujek-Zdunek, Magdalena Tomasiewicz, Krzysztof Belica-Wdowik, Teresa Pabjan, Paweł Lorenc, Beata Czauż-Andrzejuk, Agnieszka Tronina, Olga Krygier, Rafał Dobracki, Witold Buczyńska, Iwona Simon, Krzysztof A. Dybowska, Dorota Halota, Waldemar Pawłowska, Małgorzata Citko, Jolanta Laurans, Łukasz Mazur, Włodzimierz Janczewska, Ewa Socha, Łukasz Deroń, Zbigniew Berak, Hanna Flisiak, Robert Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting |
title | Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting |
title_full | Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting |
title_fullStr | Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting |
title_full_unstemmed | Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting |
title_short | Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting |
title_sort | efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis c patients eligible for 8-week regimen in a real-world setting |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9710286/ https://www.ncbi.nlm.nih.gov/pubmed/36457986 http://dx.doi.org/10.5114/aoms.2019.86569 |
work_keys_str_mv | AT zarebskamichalukdorota efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT piekarskaanna efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT jaroszewiczjerzy efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT klapaczynskijakub efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT sitkomarek efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT tudrujekzdunekmagdalena efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT tomasiewiczkrzysztof efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT belicawdowikteresa efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT pabjanpaweł efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT lorencbeata efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT czauzandrzejukagnieszka efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT troninaolga efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT krygierrafał efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT dobrackiwitold efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT buczynskaiwona efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT simonkrzysztofa efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT dybowskadorota efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT halotawaldemar efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT pawłowskamałgorzata efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT citkojolanta efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT lauransłukasz efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT mazurwłodzimierz efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT janczewskaewa efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT sochałukasz efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT deronzbigniew efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT berakhanna efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting AT flisiakrobert efficacyof8versus12weektreatmentwithledipasvirsofosbuvirinchronichepatitiscpatientseligiblefor8weekregimeninarealworldsetting |